Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs MGM Resorts International (MGM) Price & Performance

Heron Therapeutics IncTrade
MGM Resorts InternationalTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs MGM Resorts International — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $61.47M), while MGM Resorts International trades at $44.01 (market cap $11.10B). The key difference: MGM Resorts International is far larger — about 180.6× Heron Therapeutics Inc's market cap, and MGM Resorts International pays a 0.03% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

HRTXMGM
Market Cap
$61.47M$11.10B
Sector
HealthConsumer Cyclical
52-Week High
$1.49$50.69
52-Week Low
$0.32$30.72
Enterprise Value
$168.21M$38.40B
Dividend Yield
0.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

MGM Resorts International

MGM Resorts International (MGM) trades at $43.36, down 2.5% with bearish technical signals despite mixed earnings performance. The company reported record Q2 2026 revenue of $17.54B but missed EPS estimates, while analyst consensus remains divided with a $51.14 price target. Recent news highlights ongoing acquisition investigations and BetMGM's expansion in Canadian markets.

MGM faces near-term pressure from earnings volatility and acquisition uncertainty, but maintains strong revenue growth and digital expansion. Key risks include regulatory scrutiny and competitive pressures, while institutional sentiment leans neutral with balanced buy/hold ratings suggesting cautious optimism for recovery.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About MGM Resorts International

MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.

Read more on MGM